2024 International Annual Patient Conference

TMA’s International Annual Patient Conference is the most celebrated event of the year for the myositis community! The 2024 conference will take place in Baltimore, Maryland on September 6-8 at the Hilton Baltimore Inner Harbor Hotel.

Virtual Sessions and Events

Conference attendees will receive access to exclusive virtual content before and after the conference. Pre-conference sessions are designed to spark learning and create connections prior to gathering in-person. Following our time in Baltimore, TMA’s new post-conference reunion will keep those connections going!

Friday, August 23 | 12:00-12:45pm ET | Virtual Conference Orientation

Friday, August 23 | 12:45-1:30pm ET | Virtual Getting Acquainted Sessions – IBM, DM, NM/ASyS, PM, Care Partners

Wednesday, August 28 | Virtual Conference Breakout Sessions

Friday, September 27 | 12:00-12:45pm ET | Virtual Conference Reunion and Staying Acquainted Sessions – IBM, DM, NM/ASyS, PM, Care Partners


Conference Breakout Sessions

Nearly 40 breakout sessions await TMA conference attendees! Expert speakers include TMA Medical Advisors, TMA research grantees, clinicians from the the Myositis Research Center at Johns Hopkins University, and investigators from the National Institutes of Health (NIH). Here’s a cross-section of the engaging content that will unfold over the three days while the myositis community is together.

Applying Cognitive Behavioral Therapy (CBT) and Mindfulness Fundamentals in Your Day-to-Day

Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Promising New Frontier for Myositis Treatment

Civilian and Military Environmental Risk Factors in Myositis

Determining Benefits Eligibility: Social Security Disability Insurance (SSDI), Medicare, and Medicaid

Empowering Patients: Navigating Assistive Technologies to Stay Connected Board of Directors Chair’s Session

Finding Strength through Faith

Hazards of Immune Boosting Supplements

Health Equity: Bridging the Gap between Experts and Patients organized in partnership with TMA Women of Color Affinity Group

Insurance Challenges

Intimacy and Relationships: How Chronic Illness Can Bring You Closer

Latest Research and Clinical Trials Insights for Dermatomyositis (DM) and Other Forms of Myositis

Latest Research and Clinical Trials Insights for Inclusion Body Myositis (IBM)

Management of Dysphagia in Myositis

Mental Health in Myositis: A Panel organized in partnership with TMA Women With IBM Affinity Group

Myositis Medications and Management

Patient Registries and Biorepositories in Myositis

Pulmonary Rehabilitation

Skin and Hair Issues in Dermatomyositis

Treatment of Myositis Interstitial Lung Disease (ILD): Immunosuppression and Beyond

Veteran Roundtable: Navigating VA Claims and Appeals organized in partnership with TMA Military Veterans with Myositis Affinity Group


Conference Content by Form of Myositis

Some of the International Annual Patient Conference is organized by diagnosis and delivered to support you specifically. Wherever you are in your myositis journey, TMA has a medical advisor who can answer your most pressing questions.

Back to Basics

  • Back to Basics: Dermatomyositis (DM) and Antisynthetase Syndrome (ASyS)
  • Back to Basics: Inclusion Body Myositis (IBM)
  • Back to Basics: Necrotizing Myopathy (NM) and Polymyositis (PM): Types, Diagnosis, Treatment

Ask the Doc

  • Ask the Doc: Antisynthetase Syndrome (ASyS) and/or Interstitial Lung Disease (ILD)
  • Ask the Doc: Dermatomyositis (DM) and/or Interstitial Lung Disease (ILD)
  • Ask the Doc: Inclusion Body Myositis (IBM) – Diagnosed More than 5 Years
  • Ask the Doc: Inclusion Body Myositis (IBM) – Diagnosed within the last 5 years
  • Ask the Doc: Necrotizing Myopathy (NM) and/or Polymyositis (PM)

Physical and Occupational Therapy

  • Physical Therapy (PT) for Inclusion Body Myositis (IBM)
  • Physical Therapy (PT) for Other Forms of Myositis
  • Occupational Therapy (OT) for All Forms of Myositis

Latest Scientific Findings

  • Latest Research and Clinical Trials Insights for Dermatomyositis (DM) and Other Forms of Myositis
  • Latest Research and Clinical Trials Insights for Inclusion Body Myositis (IBM)
  • Severe Forms of Myositis and Complications: Antisynthetase Syndrome (ASyS), MDA5 Dermatomyositis (DM), Interstitial Lung Disease (ILD), and Other

Our Distinguished Speakers

Laurie Boyer, MBA, District Administrator, Magnet Schools Coordinator, Curriculum Developer, Technology Specialist, St. Lucie Public Schools, Florida; Cofounded and Former Vice President, former Team Tommy Foundation; Chair, Board of Directors, The Myositis Association.

Lisa Christopher-Stine, MD, MPH, FACR, Rheumatologist; Professor of Medicine and Professor of Neurology, Johns Hopkins University School of Medicine; Cofounder and Director, Johns Hopkins Myositis Center; Co-Chair Johns Hopkins Institutional Review Board; Cochair, OMERACT Myositis Working Group for Patient Reported Outcome Measures; Deputy Director of Telemedicine in the Division of Rheumatology; Member, TMA Medical Advisory Board.

Sonye Danoff, MD, PhD, FACCP, FATSF, Pulmonologist; Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Codirector of the Interstitial Lung Disease Program, and Associate Director of the Myositis Center at Johns Hopkins University School of Medicine; Member, Johns Hopkins Department of Medicine, Task Force on Women’s Academic Careers in Medicine; Senior Medical Advisor, Care Center Network, Pulmonary Fibrosis Foundation; Member, Scientific Advisory Committee of Global Conference on Myositis (GCOM); Member, TMA Medical Advisory Board; Former Member, Research Grant Review Committee, The Myositis Association.

Namita A. Goyal, MD, FAAN, Neurologist; Professor of Neurology, University of California, Irvine School of Medicine; Codirector, UC Irvine-MDA ALS and Neuromuscular Center; Director, Neuromuscular Medicine Fellowship; Director, ALS Clinic at University of California, Irvine; Member, FDA Advisory Committee for ALS Studies, Center for Drug Evaluation and Research (CDER); Chair, TMA Medical Advisory Board.

Valérie Leclair, MD, PhD, BScErg, FRCPC, Rheumatologist and Epidemiologist; Assistant Professor, Department of Medicine, McGill University; Member, TMA Medical Advisory Board.

Tahseen Mozaffar, MD, Neurologist; Professor of Neurology, Pathology, and Laboratory Medicine and Orthopaedic Surgery, University of California, Irvine; Chair, Institutional Review Board; Director, Division of Neuromuscular Diseases, Neurology; Director, UCI-MDA ALS and Neuromuscular Center; Affiliate Faculty, Institute for Memory Impairments and Neurological Disorders (UCI MIND); Former Member, TMA Medical Advisory Board; Member, Board of Directors and Liaison to the Medical Advisory Board, The Myositis Association.

Merrilee Needham, MBBS, FRACP, PhD, Neurologist; Head, Department of Neurology, Fiona Stanley Hospital (Australia); Head, Neuromuscular and Myositis Research, The Perron Institute for Neurological and Translational Science; Professor of Neurology, Murdoch University and University of Notre Dame Australia; Consultant Neurologist, Fremantle Hospital; Established Myositis Discovery Programme (MyoPD) in Western Australia; Member, TMA Medical Advisory Board.

Julie Paik, MD, MHS, Rheumatologist; Associate Professor of Medicine, Johns Hopkins University; Codirector of the Johns Hopkins Myositis Center; Director of Clinical Trials, Johns Hopkins Myositis Center; Chair, Meeting Planning Committee, International Myositis Assessment and Clinical Studies Group (IMACS); Vice Chair, TMA Medical Advisory Board. Dr. Paik is the Co-Director of the Myositis Center and an Associate Professor of Medicine in the Division of Rheumatology.

Lisa G. Rider, MD, FACR, FAAP, Pediatric Rheumatologist; Head and Senior Clinician, Environmental Autoimmunity Group; Clinical Research Branch of the National Institute of Environmental Health Sciences, National Institutes of Health; Adjunct Professor, Department of Pediatrics, Uniformed Services University of Health Sciences (USUHS); Clinical Professor of Medicine, George Washington University; Cofounder and Colead of the International Myositis Assessment and Clinical Studies (IMACS) Group; Vice Chair, International Myositis Genetics Consortium (MYOGEN); Member Steering Committee and Scientific Committees, Global Conference on Myositis 2014-2022; Chair of Medical Advisory Board, Cure JM Foundation; former Member, Vice Chair, and Chair of Research Committee and Nominating Committee, TMA Medical Advisory Board.

Adam Schiffenbauer, MD, Rheumatologist; Deputy Head and Associate Research Physician, Environmental Autoimmunity Group; Clinical Investigator in Rheumatology, Clinical Research Branch of the National Institute of Environmental Health Sciences (NIAMS), National Institutes of Health; Faculty in the NIAMS Rheumatology Fellowship Program; Attending Consultant for Rheumatology; former Chair of the International Myositis Assessment and Clinical Studies Group (IMACS) Scientific Committee and Chair of the IMACS ICD Coding Group; Member, TMA Medical Advisory Board; Steering Committee Member, George Washington University Myositis Center—Cure JM Center of Excellence.

Victoria P. Werth, MD, Dermatologist; Chief of Dermatology, Philadelphia Veteran’s Administration Hospital; Professor of Dermatology and Medicine, University of Pennsylvania School of Medicine and the Veteran’s Administration Medical Center; Dermatology Consultant Penn Medicine; Founding Member, Rheumatologic Dermatology Society; Founding Member, Medical Dermatology Society; Member, TMA Medical Advisory Board; Former Member, Research Grant Review Committee, The Myositis Association; Member Organizing Committee, Global Conference on Myositis 2017-2024.